NeuroSense Therapeutics has made significant strides toward bringing its innovative ALS treatment, PrimeC, to the Canadian market. Health Canada has invited the company to a pre-New Drug Submission meeting to discuss a potential conditional regulatory pathway for the drug, marking a critical step in the company’s commercialization strategy.
PrimeC is a novel extended-release oral formulation that combines ciprofloxacin and celecoxib. Clinical trials, including the Phase 2b PARADIGM study, have demonstrated promising results, showing a 36% reduction in disease progression and a 43% improvement in survival rates compared to placebo.
The company aims to secure potential approval in Canada by the first half of 2026, with estimated peak annual revenue potential of $100-150 million in the Canadian market. This development comes alongside NeuroSense’s broader global strategy, which includes positive FDA feedback on its Phase 3 trial design and plans to initiate the pivotal study in mid-2025.
The pharmaceutical industry has shown significant interest in neurological innovations, as evidenced by recent high-value licensing deals. Collaborations such as GlaxoSmithKline’s $700 million upfront payment to Alector in 2021 and Biogen’s $560 million partnership with Denali Therapeutics in 2020 demonstrate the potential value of breakthrough neurological treatments.
In December 2024, NeuroSense also announced entering a binding term sheet with a global pharmaceutical company to advance PrimeC’s development, which includes substantial upfront payments and funding for the Phase 3 program. The Canadian regulatory pathway represents a potential avenue for earlier commercialization while the global Phase 3 program continues.
The advancement of PrimeC could represent a significant breakthrough for ALS patients, offering hope for a treatment that demonstrates meaningful improvements in disease progression and patient survival. As NeuroSense continues to navigate regulatory landscapes, the potential for PrimeC to address the critical unmet needs of ALS patients remains a focal point of the company’s research and development efforts.
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is NeuroSense Advances ALS Treatment PrimeC Toward Canadian Market with Promising Regulatory Pathway.